HPV (Papilloma Human Virus) Vaccination in Young Women With Cystic Fibrosis and Followed in the Auvergne Rhône-Alpes Region
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Human Papillomavirus Infection
- Sponsor
- Hospices Civils de Lyon
- Enrollment
- 74
- Locations
- 3
- Primary Endpoint
- Realization of human papillomavirus vaccination
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The main risk factor for the development of cervical lesions is human papillomavirus (HPV) infection. Vaccination against human papillomavirus, which is offered to all girls aged 11 to 14, and catching up to girls aged 15 to 19, is an effective method of preventing cervical pathology. Despite this, human papillomavirus vaccination coverage remains low in France.
Some women with cystic fibrosis might need a transplantation, which is a factor associated with increased risk of human papillomavirus carriage and cervical pathology. An over-risk of cervical pathology would also be present in non-transplanted women with cystic fibrosis. Particular attention should therefore be paid to vaccination in this population.
The objective is to estimate the frequency of human papillomavirus vaccination in young patients with cystic fibrosis, and to evaluate the reasons for non-vaccination.
Investigators
Eligibility Criteria
Inclusion Criteria
- •girls with Cystic Fibrosis
- •followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA)
- •aged 11 years or older
Exclusion Criteria
- •Refusal to respond to the questionnaire
Outcomes
Primary Outcomes
Realization of human papillomavirus vaccination
Time Frame: 15 minutes
The main outcome is the prevalence of human papillomavirus vaccination in young women with Cystic fibrosis. This data is collected using a questionnaire : HPV vaccination performed : yes/no
Secondary Outcomes
- Respect for the vaccinal plan(15 minutes)
- Type of vaccine used(15 minutes)
- Reasons for non-vaccination(15 minutes)